Palbociclib is prescribed for:
- HR-positive, HER2-negative advanced breast cancer
- With aromatase inhibitor (initial therapy)
- With fulvestrant (after progression)
- Oncology targeted therapy
First CDK4/6 inhibitor approved for breast cancer.
Generic Name: Palbociclib
Brand Names: Ibrance
Palbociclib is a CDK4/6 inhibitor used with hormone therapy for advanced HR+/HER2- breast cancer.
Palbociclib is prescribed for:
First CDK4/6 inhibitor approved for breast cancer.
Common side effects:
Serious side effects:
Palbociclib is a CDK4/6 inhibitor that blocks cell cycle progression in cancer cells.
Neutropenia is expected - requires regular blood count monitoring and dose adjustments.
Given in 21-day cycles with 1 week off to allow blood counts to recover.
Learn more at MedlinePlus.
This medication is commonly used to treat or manage the following conditions:
Anemia, characterized by a low red blood cell count, leads to fatigue and weakness due to reduced oxygen delivery; causes include blood loss, decreased production, and chronic diseases.
Neutropenia, a deficiency of infection-fighting neutrophils, arises from impaired bone marrow production (congenital/acquired), increased destruction (autoimmune), infections, medications, or toxin exposure.
Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.
Loading questions...
Have questions about Palbociclib? Get expert answers from Dr. Zimmer.
Privacy: Your questions are posted anonymously for your health privacy. Your name and email are only used for admin purposes.
Questions are reviewed before posting. You'll see your question and Dr. Zimmer's answer below once approved.